HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Quote:
Login Free Membership
Search:

Analyst Blog  

DaVita Unit Acquires in Germany

Share
By: Zacks Equity Research
November 10, 2011 | Comment(s): 0
Recommended this article (6)
DVA | LNCR | HLS

Yesterday, DaVita Inc. (DVA - Analyst Report) announced the acquisition of ExtraCorp AG by its wholly-owned subsidiary DV Care GmbH. ExtraCorp is a German company that owns and operates two dialysis centers in Salzgitter and Seesen and manages two other dialysis centers in Dresden and Freital. All four centers provide a wide variety of dialysis services, of which hemodialysis is the most important one.

Acquisitions have been DaVita’s preferred growth strategy over the years and the company has slowly started moving into the international market. It already has dialysis centers in Singapore and India and has signed an agreement to build some in Malaysia.

Additionally, it is trying to expand its presence in Europe. DaVita has been looking for acquisition and partnership opportunities in all major European and Asian countries over the past year. At the same time, the company is also looking at domestic acquisitions. In September 2011, DaVita completed the acquisition of its competitor DSI Renal Inc.

Earnings Review

DaVita reported third-quarter income from continuing operations of $138.2 million, or $1.45 per share, which exceeded the Zacks Consensus Estimate by a penny.

Further, the Zacks Consensus Estimate for DaVita’s fourth-quarter earnings is currently at $1.48 per share, up about 31% year-over-year. Of the 13 firms covering the stock, 11 revised their estimates upward, while 1 downward revision was witnessed in the last 30 days.

For 2011, earnings are expected to be about $5.05 per share, climbing about 15% year-over-year. The company competes with Lincare Holdings Inc. (LNCR - Snapshot Report) and HealthSouth Corporation (HLS - Snapshot Report). Currently, DaVita caries a Zacks #2 Rank, implying a short term Buy rating.

On Wednesday, the shares of the company closed at $72.68, down 2.39%, on the New York Stock Exchange.

Read the full analyst report on DVA

Read the full analyst report on LNCR

Read the full analyst report on HLS

 

Please login to Zacks.com or register to post a comment.



Email

Print

Share

Rate Pos

Rate Neg
Attn. Zacks.com Visitors
Sell These Stocks Today
Make sure no Zacks #5 Rank "Strong Sell" stocks are lurking in your portfolio. They tend to perform only 1/6th as well as the market!
Get your free Welcome Gifts today*:
 1.  Zacks "Strong Sell" list.
 2.  Our e-newsletter with 4 "Strong Buy" stocks, Bull & Bear of the Day, and market commentary in every issue.
Get them free right now
  
No cost. Unsubscribe anytime. Privacy Policy
*Only for non-members. May end at any time.

More Zacks Resources

Market Summary May 26, 2012 16:17 pm ET
DJIA 12454.83  -74.92 -0.60%
NASD 2837.53  -1.85 -0.07%
S&P 500 1317.82  -2.86 -0.22%
Partner Center